Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Merrill JT, Petri MA, Buyon J, Ramsey-Goldman R, Kalunian K, Putterman C, Conklin J, Furie RA, Dervieux T.

Lupus Sci Med. 2018 May 23;5(1):e000263. doi: 10.1136/lupus-2018-000263. eCollection 2018.

2.

Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.

Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.

Arthritis Rheumatol. 2018 Jun;70(6):868-877. doi: 10.1002/art.40439. Epub 2018 Apr 25.

3.

Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.

Furie RA, Mitrane M, Zhao E, Becker PM.

Lupus Sci Med. 2017 Dec 27;4(1):e000240. doi: 10.1136/lupus-2017-000240. eCollection 2017.

4.

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.

Kalunian KC, Urowitz MB, Isenberg D, Merrill JT, Petri M, Furie RA, Morgan-Cox MA, Taha R, Watts S, Silk M, Linnik MD.

Rheumatology (Oxford). 2018 Jan 1;57(1):125-133. doi: 10.1093/rheumatology/kex368.

PMID:
29045736
5.

Antiphospholipid Syndrome: It's Far More Than You Think.

Annem C, Furie RA.

J Clin Rheumatol. 2017 Aug;23(5):278-284. doi: 10.1097/RHU.0000000000000564. No abstract available.

PMID:
28742725
6.

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.

Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C; EMBODY Investigator Group.

Arthritis Rheumatol. 2017 Feb;69(2):362-375. doi: 10.1002/art.39856.

7.
8.

Reply.

Pope JE, Rothfield NF, Ramsey-Goldman R, Douglas Smith C, Bernatsky SR, Furie RA, Hudson M, Burgos-Vargas R, Senécal JL, Inanç M, van Vollenhoven RF, Chandran V, Nash PT, Muangchan C.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):1053-4. doi: 10.1002/acr.22777. No abstract available.

9.

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.

Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, Starr AJ, Imundo LF, Buyon J, Furie RA, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, van Vollenhoven RF, Wallace DJ, Askanase A.

J Rheumatol. 2015 Dec;42(12):2288-95. doi: 10.3899/jrheum.150470. Epub 2015 Nov 1.

10.

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, Dörner T.

Ann Rheum Dis. 2016 Feb;75(2):332-40. doi: 10.1136/annrheumdis-2015-207654. Epub 2015 Aug 20.

PMID:
26293163
11.

Treatment Algorithms in Systemic Lupus Erythematosus.

Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inanç M, Rothfield NF, Nash PT, Furie RA, Senécal JL, Chandran V, Burgos-Vargas R, Ramsey-Goldman R, Pope JE.

Arthritis Care Res (Hoboken). 2015 Sep;67(9):1237-45. doi: 10.1002/acr.22589.

12.

Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.

Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B.

Blood. 2014 Jul 24;124(4):611-22. doi: 10.1182/blood-2014-02-554980. Epub 2014 May 13.

13.

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study.

Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144. Epub 2014 Apr 19.

PMID:
24748629
14.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

15.

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, Houssiau FA, Drappa J, Close D, Maciuca R, Rao K, Shahdad S, Brunetta P.

Arthritis Rheum. 2013 Sep;65(9):2368-79. doi: 10.1002/art.38037.

16.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
17.

Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.

Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, Chitkara P, Putterman C, Gross RL, Somers EC, Kirou KA, Ramsey-Goldman R, Hsieh C, Buyon JP, Dervieux T, Weinstein A.

Arthritis Rheum. 2012 Dec;64(12):4040-7. doi: 10.1002/art.34669.

18.

Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).

Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, Brunetta P.

Lupus. 2011 Jun;20(7):709-16. doi: 10.1177/0961203310395802. Epub 2011 Apr 8.

PMID:
21478286
19.

β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.

Arad A, Proulle V, Furie RA, Furie BC, Furie B.

Blood. 2011 Mar 24;117(12):3453-9. doi: 10.1182/blood-2010-08-300715. Epub 2011 Jan 18.

20.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

21.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

22.

Abetimus sodium: a medication for the prevention of lupus nephritis flares.

Horowitz DM, Furie RA.

Expert Opin Pharmacother. 2009 Jun;10(9):1501-7. doi: 10.1517/14656560902946419. Review.

PMID:
19505217
23.

Pulmonary manifestations of primary Sjögren's syndrome.

Sarkar PK, Patel N, Furie RA, Talwar A.

Indian J Chest Dis Allied Sci. 2009 Apr-Jun;51(2):93-101. Review.

PMID:
19445445
24.

Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.

Mease PJ, Reich K; Alefacept in Psoriatic Arthritis Study Group.

J Am Acad Dermatol. 2009 Mar;60(3):402-11. doi: 10.1016/j.jaad.2008.09.050. Epub 2008 Nov 25. Erratum in: J Am Acad Dermatol. 2009 Sep;61(3):507.

PMID:
19028407
25.

Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.

Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD; LJP 394-90-09 Investigator Consortium.

Arthritis Rheum. 2008 Aug;58(8):2470-80. doi: 10.1002/art.23673.

26.

Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.

Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE.

J Rheumatol. 2008 Aug;35(8):1567-75. Epub 2008 Jul 15.

PMID:
18634158
27.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group.

Arthritis Rheum. 2006 Sep;54(9):2793-806.

28.

Diversification of the Ig variable region gene repertoire of synovial B lymphocytes by nucleotide insertion and deletion.

Miura Y, Chu CC, Dines DM, Asnis SE, Furie RA, Chiorazzi N.

Mol Med. 2003 May-Aug;9(5-8):166-74.

29.

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.

Alarcón-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B; LJP 394 Investigator Consortium.

Arthritis Rheum. 2003 Feb;48(2):442-54.

30.

Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.

McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Linnik MD.

Lupus. 2001;10(8):526-32.

PMID:
11530993
31.

Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I.

McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, Victoria EJ, Linnik MD.

Thromb Haemost. 2001 Aug;86(2):590-5.

PMID:
11522008
32.

Treatment of systemic lupus erythematosus with LJP 394.

Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Liebling MR, Hudson NP, Berner CM, Coutts S, de Haan HA.

J Rheumatol. 2001 Feb;28(2):257-65.

PMID:
11246659
33.

Clonal expansion is a characteristic feature of the B-cell repetoire of patients with rheumatoid arthritis.

Itoh K, Patki V, Furie RA, Chartash EK, Jain RI, Lane L, Asnis SE, Chiorazzi N.

Arthritis Res. 2000;2(1):50-8.

34.

Immunoglobulin heavy chain variable region gene replacement As a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes.

Itoh K, Meffre E, Albesiano E, Farber A, Dines D, Stein P, Asnis SE, Furie RA, Jain RI, Chiorazzi N.

J Exp Med. 2000 Oct 16;192(8):1151-64.

35.

A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome.

Hirose N, Williams R, Alberts AR, Furie RA, Chartash EK, Jain RI, Sison C, Lahita RG, Merrill JT, Cucurull E, Gharavi AE, Sammaritano LR, Salmon JE, Hashimoto S, Sawada T, Chu CC, Gregersen PK, Chiorazzi N.

Arthritis Rheum. 1999 Aug;42(8):1655-61.

36.

Reversible monocular blindness complicating Churg-Strauss syndrome.

Alberts AR, Lasonde R, Ackerman KR, Chartash EK, Susin M, Furie RA.

J Rheumatol. 1994 Feb;21(2):363-5.

PMID:
8182653
37.

Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides.

García Moncó JC, Wheeler CM, Benach JL, Furie RA, Lukehart SA, Stanek G, Steere AC.

J Neurol Sci. 1993 Jul;117(1-2):206-14.

PMID:
8410057
38.

Cardiac manifestations of the antiphospholipid syndrome.

Kaplan SD, Chartash EK, Pizzarello RA, Furie RA.

Am Heart J. 1992 Nov;124(5):1331-8. Review.

PMID:
1442504
39.

Septic subdeltoid bursitis.

Chartash EK, Good PK, Gould ES, Furie RA.

Semin Arthritis Rheum. 1992 Aug;22(1):25-9. Review.

PMID:
1411579
40.

Effects of human immunodeficiency virus infection on the expression of rheumatic illness.

Furie RA.

Rheum Dis Clin North Am. 1991 Feb;17(1):177-88. Review.

PMID:
2041886
41.

L-tryptophan induced eosinophilia-myalgia syndrome.

Chartash EK, Given WP, Vishnubhakat SM, Susin M, Coffey EL Jr, Farmer PM, Albanese JM, Kaplan MH, Furie RA.

J Rheumatol. 1990 Nov;17(11):1527-33.

PMID:
2273498
42.

Cardiac tamponade as an initial manifestation of systemic lupus erythematosus.

Reiner JS, Furie RA.

J Rheumatol. 1989 Aug;16(8):1127-9. Review.

PMID:
2685297
43.

Tendon rupture in systemic lupus erythematosus.

Furie RA, Chartash EK.

Semin Arthritis Rheum. 1988 Nov;18(2):127-33. Review.

PMID:
3064304
44.

Pasteurella multocida infection; report in urban setting and review of spectrum of human disease.

Furie RA, Cohen RP, Hartman BJ, Roberts RB.

N Y State J Med. 1980 Sep;80(10):1597-602. Review. No abstract available.

PMID:
6999394

Supplemental Content

Loading ...
Support Center